Pharmacologic intervention for attention-deficit hyperactivity disorder in preschoolers: Is it justified?

Pediatric Drugs

Volumn 15, Issue 1, 2013, Pages 1-8

  Ghuman, Jaswinder K ^a   Ghuman, Harinder S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; PLACEBO;

AGGRESSION; ANXIETY; APPETITE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COGNITIVE THERAPY; CONSTIPATION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FAINTNESS; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GROWTH ACCELERATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERACTIVITY; IRRITABILITY; METABOLIC DISORDER; MINIMAL BRAIN DYSFUNCTION; OPPOSITIONAL DEFIANT DISORDER; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; REVIEW; SEDATION; SIDE EFFECT; SLEEP; THIRST; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; HUMANS; INFORMED CONSENT; METHYLPHENIDATE; OFF-LABEL USE;

EID: 84873362246     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-012-0001-5     Document Type: Review

References (59)

1. Egger HL, Angold A. Common emotional and behavioral disorders in preschool children: presentation, nosology, and epidemiology. J Child Psychol Psychiatry. 2006;47(3-4):313-37.
2. McDonnell M, Glod C. Prevalence of psychopathology in preschool-age children. J Child Adolesc Psychiatr Nursing. 2003;16(4):141-52.
3. Campbell SB, Shaw DS, Gilliom M. Early externalizing behavior problems: toddlers and preschoolers at risk for later maladjustment. Dev Psychopathol. 2000;12(3):467-88.
4. Ghuman J, Arnold L, Anthony B. Psychopharmacological and other treatments in preschool children with attention-deficit/hyperactivity disorder: current evidence and practice. J Child Adolesc Psychopharmacol. 2008;18(5):413-47.
5. Rappley MD, Mullan PB, Alvarez FJ, et al. Diagnosis of attention-deficit/hyperactivity disorder and use of psychotropic medication in very young children. Arch Pediatr Adolesc Med. 1999;153(10):1039-45.
6. Baker B, Neece C, Fenning R, et al. Mental disorders in five-year-old children with or without developmental delay: focus on ADHD. J Clin Child Adolesc Psychol. 2010;39(4):492-505.
7. Campbell SB, Ewing LJ. Follow-up of hard-to-manage preschoolers: adjustment at age 9 and predictors of continuing symptoms. J Child Psychol Psychiatry. 1990;31(6):871-89.
8. Pliszka S, on behalf of the AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.
9. Zito JM, Safer DJ, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283(8):1025-30.
10. Zito JM, Safer DJ, Valluri S. Psychotherapeutic medication prevalence in Medicaid-insured preschoolers. J Child Adolesc Psychopharmacol. 2007;17(2):195-203.
11. Evans W, Morrill M, Parente S. Measuring inappropriate medical diagnosis and treatment in survey data: the case of ADHD among school-age children. J Health Econ. 2010;29(5):657-73.
12. Hood KK, Eyberg SM. Outcomes of parent-child interaction therapy: mothers' reports of maintenance three to six years after treatment. J Clin Child Adolesc Psychol. 2003;32(3):419-29.
13. Jones K, Daley D, Hutchings J, et al. Efficacy of the incredible years basic parent training programme as an early intervention for children with conduct problems and ADHD. Child Care Health Dev. 2007;33(6):749-56.
14. Kern L, DuPaul G, Volpe R, et al. Multisetting assessment-based intervention for young children at risk for attention deficit hyperactivity disorder: initial effects on academic and behavioral functioning. School Psychol Rev. 2007;36(2):237-55.
15. Sonuga-Barke EJ, Daley D, Thompson M, et al. Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample. J Am Acad Child Adolesc Psychiatry. 2001;40(4):402-8.
16. Webster-Stratton C, Reid M, Beauchaine T. Combining parent and child training for young children with ADHD. J Clin Child Adolesc Psychol. 2011;40(2):191-203.
17. Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1284-93.
18. Dulcan MK, Benson RS. AACAP Official Action. Summary of the practice parameters for the assessment and treatment of children, adolescents, and adults with ADHD. J Am Acad Child Adolesc Psychiatry. 1997;36(9):1311-7.
19. Gleason MM, Egger HL, Emslie GJ, et al. Psychopharmacological treatment for very young children: contexts and guidelines. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1532-72.
20. Barkley RA, Shelton TL, Crosswait C, et al. Multi-method psycho-educational intervention for preschool children with disruptive behavior: preliminary results at post-treatment. J Child Psychol Psychiatry. 2000;41(3):319-32.
21. Shelton TL, Barkley RA, Crosswait C, et al. Multimethod psychoeducational intervention for preschool children with disruptive behavior: two-year post-treatment follow-up. J Abnorm Child Psychol. 2000;28(3):253-66.
22. Dreyer A, O'Laughlin L, Moore J, et al. Parental adherence to clinical recommendations in an ADHD evaluation clinic. J Clin Psychol. 2010;66(10):1101-20.
23. MacNaughton KL, Rodrigue JR. Predicting adherence to recommendations by parents of clinic-referred children. J Consult Clin Psychol. 2001;69(2):262-70.
24. Pelsser L, Frankena K, Toorman J, et al. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet. 2011;377(9764):494-503.
25. Ghuman J. Restricted elimination diet for ADHD: the INCA study. Lancet. 2011;377(9764):446-8.
26. Van Brunt DL, Johnston JA, Ye WY, et al. Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder. Pharmacotherapy. 2005;25(11):1541-9.
27. Luby J, Mrakotsky C, Stalets MM, et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol. 2006;16(5):575-87.
28. Olfson M, Crystal S, Huang C, et al. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49(1):13-23.
29. Ghuman JK, Ginsburg GS, Subramaniam G, et al. Psychostimulants in preschool children with attention-deficit/hyperactivity disorder: clinical evidence from a developmental disorders institution. J Am Acad Child Adolesc Psychiatry. 2001;40(5):516-24.
30. Ghuman J, Aman M, Lecavalier L, et al. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol. 2009;19(4):329-39.
31. Greenhill L, Swanson J, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40(2):180-7.
32. Ghuman JK, Riddle MA, Vitiello B, et al. Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol. 2007;17(5):563-80.
33. Vitiello B, Abikoff H, Chuang S, et al. Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/ Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol. 2007;17(5):593-604.
34. Wigal S, Gupta S, Greenhill L, et al. Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007;17(2):153-64.
35. Wigal T, Greenhill L, Chuang S, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1294-303.
36. Kratochvil C, Vaughan B, Stoner J, et al. A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. Pediatrics. 2011;127(4):862-8.
37. Ghuman J, Aman M, Ghuman H, et al. Prospective, naturalistic, pilot study of open-label atomoxetine treatment in preschool children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19(2):155-66.
38. Ghuman J, Cataldo M, Beck M, et al. Behavioral training for pill-swallowing difficulties in young children with autistic disorder. J Child Adolesc Psychopharmacol. 2004;14(4):601-11.
39. Ghuman J, Byreddy S, Ghuman H. Methylphenidate transdermal system in preschool children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011;21(5):495-8.
40. Glantz L, Gilmore J, Hamer R, et al. Synaptophysin and postsynaptic density protein 95 in the human prefrontal cortex from mid-gestation into early adulthood. Neuroscience. 2007;149(3):582-91.
41. Huttenlocher PR. Morphometric study of human cerebral cortex development. Neuropsychologia. 1990;28(6):517-27.
42. Chugani HT. Positron emission tomography: principles and applications in pediatrics. Mead Johnson Symp Perinat Dev Med. 1987;25:15-8.
43. Chugani H. A critical period of brain development: studies of cerebral glucose utilization with PET. Prev Med. 1998;27(2):184-8.
44. Crandall J, McCarthy D, Araki K, et al. Dopamine receptor activation modulates GABA neuron migration from the basal forebrain to the cerebral cortex. J Neurosci. 2007;27(14):3813-22.
45. Nasrallah H, Loney J, Olson S, et al. Cortical atrophy in young adults with a history of hyperactivity in childhood. Psychiatry Res. 1986;17(3):241-6.
46. Lou H, Hendricksen L, Bruhn P. Focal cerebral hypoperfusion in children with dysphasia and/or attention deficit disorder. Arch Neurol. 1984;41:825-9.
47. Shaw P, Sharp W, Morrison M, et al. Psychostimulant treatment and the developing cortex in attention deficit hyperactivity disorder. Am J Psychiatry. 2009;166(1):58-63.
48. Swanson J, Greenhill L, Wigal T, et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1304-13.
49. Food and Drug Administration. Drug Safety and Risk Management Advisory Committee meeting, February 9, 2006: briefing January 12, 2006 [online]. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4202B1-05-FDA-Tab05.pdf [Accessed 2012 Jan 27].
50. Nissen S. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354(14):1445-8.
51. Schelleman H, Bilker W, Strom B, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127(6):1102-10.
52. Gould M, Walsh B, Munfakh J, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009;166(9):992-1001.
53. El-Zein RA, Abdel-Rahman SZ, Hay MJ, et al. Cytogenetic effects in children treated with methylphenidate. Cancer Lett. 2005;230(2):284-91.
54. Tucker J, Suter W, Petibone D, et al. Cytogenetic assessment of methylphenidate treatment in pediatric patients treated for attention deficit hyperactivity disorder. Mutat Res. 2009;677(1-2):53-8.
55. Walitza S, Kampf K, Artamonov N, et al. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy. Toxicol Lett. 2009;184(1):38-43.
56. Walitza S, Kampf K, Oli R, et al. Prospective follow-up studies found no chromosomal mutagenicity of methylphenidate therapy in ADHD affected children. Toxicol Lett. 2010;193(1):4-8.
57. Zamora-Perez A, Lazalde-Ramos B, Sosa-Maclas M, et al. Methylphenidate lacks genotoxic effects in mouse peripheral blood erythrocytes. Drug Chem Toxicol. 2011;34(3):294-9.
58. Perrin J, Friedman R, Knilans T et al. on behalf of the Black Box Working Group and the Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008; 122(2):451-3.
59. Vetter V, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(8):2407-23.